Given a passage, construct a question on the basis of the information present in the passage. Construct the question in such a way that (i) it is unambiguous, (ii) it is answerable from the passage, (iii) its answer is unique (iv) it answer uses text phrases from the passage. Avoid creating questions that (i) can't be answered correctly without actually understanding the passage and (ii) uses the same words or phrases given in the passage.

Q: We investigated the clinical significance of GALNT4 expression in patients with clear cell renal cell carcinoma.', 'Enrolled in this study were 104 patients treated with curative nephrectomy at Zhongshan Hospital, Shanghai during 2004. Of the cohort 23 patients died of disease, 33 experienced recurrence and 3 died of another cause. GALNT4 density was assessed by immunohistochemistry in patient specimens. Univariate and multivariate Cox models, and ROC analysis were used to analyze the impact of prognostic factors on overall and relapse-free survival. Kaplan-Meier analysis with the log rank test was done to compare clinical outcomes between subgroups.', 'Intratumor GALNT4 expression was significantly lower than peritumor expression. Low GALNT4 expression was associated with poor overall and relapse-free survival (p = 0.001 and 0.004, respectively). Intratumor GALNT4 expression, which negatively correlated with tumor size (p = 0.032), necrosis (p\xa0=\xa00.013) and TNM stage (p = 0.017), was an independent prognostic indicator for overall and relapse-free survival (HR 3.088, p = 0.020 and 2.173, p = 0.047, respectively). Extending the TNM staging system according to GALNT4 expression showed a better prognostic value for overall and relapse-free survival (AUC 0.786, p = 0.029 and 0.761, p = 0.040, respectively).

A: Does gALNT4 predict clinical outcome in patients with clear cell renal cell carcinoma?
****
Q: The antifibrotic substance pirfenidone and the angiotensin II type I receptor antagonist candesartan cilexetil, given alone and in combination, were tested in rats with chronic anti-glomerular basement membrane glomerulonephritis (anti-GBM GN).', 'Male Wistar rats with anti-GBM GN were treated for 8 weeks with candesartan (4 mg/kg body weight/day), pirfenidone (500 mg/kg body weight/day) or a combination of both drugs. One GN group received no treatment and untreated non-GN-rats were used as controls. Blood pressure and urinary protein excretion were measured after 3 and 7 weeks. Kidney histology was complemented by ultrastructural investigation and by quantification of collagen Ialpha mRNA.', 'The percentage of glomeruli with adsorption droplets in podocytes correlated well with the amount of proteinuria (r = 0.873, P<0.01) and was significantly lowered in rats treated with candesartan (8.3 vs GN 24.6%), pirfenidone (9.8%) and combined treatment (2.6%, P<0.05 vs candesartan alone). A comparable lowering was seen for segmental sclerosis (GN 11%, candesartan 0.7%, P<0.05 vs GN, pirfenidone 1.8%, P = 0.09 vs GN, candesartan/pirfenidone 0.1%, P>0.5 vs candesartan alone). Cortical collagen Ialpha mRNA expression was significantly decreased in all treatment groups. Ultrastructural investigation showed an amelioration of basement membrane alterations and podocyte damage in the treatment groups. Candesartan caused significant blood pressure reduction and the effect was significantly enhanced by combination therapy after 3 weeks. Rats treated with pirfenidone showed blood pressure values similar to control rats.

A: Do pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats?
****
Q: To investigate the feasibility of human dermal fibroblasts in vitro differentiation into chondrogenic phenotype with induction of cartilage-derived morphogenetic protein (CDMP) growth factor.', 'Human dermal fibroblasts were isolated from foreskin and cultured in monolayer ex vivo. Dermal fibroblasts of passage2 was plated at density of 1 x 10(4) cells/cm(2) and induced with CDMP1 (100 ng/ml) in medium of F12 + 10% FBS. After 7 days of induction, morphology of cells was observed under phase-contrast microscopy and the length:width ratio of cells was calculated by Image Plus software analysis. Expression of type I, II, III collagen was detected by immunofluorescence and observed with confocal microscopy. The method of Western-Blot was applied to detect secretion of collagen type II. mRNA expression of chondrogenic related Sox9, Aggrecan as well as collagen type II, IX was detected by RT-PCR. The osteogenic related expression of collagen type X, Alkaline Phosphatase (AKP) was also detected by RT-PCR. Pellet cultured dermal fibroblasts at a density of 2 x 10(7) cells/ml was observed respectively for proteoglycan and collagen type II expression with Alcian blue and immunohistochemistry staining.', 'With the induction of CDMP1, the morphology of cells changed from spindle fibroblastic appearance to that of typical chondrocyte-like polygon shape. By Image Plus software analysis, it was found that the length/width ratio changed significantly from 7.40 +/- 1.30 of preinduction to 1.40 +/- 0.15 of post-induction (P < 0.05). No significant difference was found between the postinduction and normal chondrocyte (1.29 +/- 0.24). By confocal microscope observation, expression of collagen type II was found intracellularly in CDMP1 treated fibroblasts. Western-Blot detection confirmed collagen type II expression by 7 days induction. RT-PCR gene expression analysis of characteristic chondrogenic related genes, such as Sox9, Aggrecan as well as collagen type II, IX, revealed induction of chondrocytic phenotype in monolayered culture upon stimulation with CDMP1 for 7 days. While osteogenic related gene expression of collagen type X, AKP was not detected by RT-PCR, which indicates that osteogenic differentiation was not initiated by CDMP1 in 7 days culture. Histological staining of proteoglycan with Alcian blue and immunohistochemical staining cartilage specific type II collagen revealed deposition of typical cartilage extracellular matrix deposition in pellet cultured fibroblasts.

A:
Does [ Cartilage-derived morphogenetic protein 1 initiate chondrogenic differentiation of human dermal fibroblasts in vitro ]?
****